Comments
Vascepa awaits FDA nod on marketing exclusivity
11.09.2012. | (Reuters) - Amarin Corp said the U.S. health regulator is yet to decide on granting exclusive marketing rights to its heart drug Vascepa, sending its shares down 3 percent In extended trading....
